Use of Donanemab in Early Symptomatic Alzheimer Disease

JAMA. 2023 Dec 19;330(23):2304. doi: 10.1001/jama.2023.21106.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Alzheimer Disease* / drug therapy
  • Amyloid beta-Peptides
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Cognition Disorders / diagnosis
  • Cognition Disorders / drug therapy
  • Humans
  • Neuropsychological Tests

Substances

  • Amyloid beta-Peptides
  • donanemab
  • Antibodies, Monoclonal, Humanized